ReviewCurrent neuropharmacology2020
The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders.
Review in Current neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 2 syntheses or guidelines pooled it, 218 citations in OpenAlex.
- Cannabinoids: Therapeutic Perspectives for Management of Orofacial Pain, Oral Inflammation and Bone Healing-A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.Molecular medicine (Cambridge, Mass.) · 2024Pooled it
- Cannabinoid treatment for autism: a proof-of-concept randomized trial.Molecular autism · 2021Trial
- Poorly labeled CBD and related cannabinoid oils marketed in Europe: a hidden risk for consumers? Insights from a long-term study.Analytical and bioanalytical chemistry · 2026Article
- Transcriptomic dissection of floral identity and trichome-derived metabolite pathways in Cannabis sativa L.Planta · 2026Article
- Hierarchical Chemotaxonomic Differentiation in Cannabis Chemovars Using Quantitative HPLC Cannabinoid Profiling and Multivariate Chemometrics.Plants (Basel, Switzerland) · 2026Article
- HiSorb-TD-GC-MS analysis of commercial CBD oils.Analytical and bioanalytical chemistry · 2026Article
- Evaluation of Anti-Inflammatory Effects ofNutrients · 2026Article
- Sanitation of medical cannabis flowers (Cannabis sativa L., flos): comparing current technologies and non-thermal plasma novelties from safety and quality perspectives.Journal of cannabis research · 2026Review
- Cannabis smoke extract disrupts trophoblast differentiation and causes mitochondrial dysfunction beyond the effects of Δ9-THC alone.Scientific reports · 2026Article
- Combined extraction and spray-freeze-drying of Cannabis sativa Flos provides stable lyophilizate particles of cannabinoids.Journal of cannabis research · 2026Article
- Interplay between the HPA axis and inflammation as mechanisms therapeutic targets ofFrontiers in pharmacology · 2026Review
- Cannabinoid efficacy for pain: dose, chronicity and route.Frontiers in neuroscience · 2026Review
- Vegetative and reproductive stage lighting interactions on flower yield, water use efficiency, terpenes, and cannabinoids of Cannabis sativa.Scientific reports · 2025Article
- Valorization of Thyme Combined with Phytocannabinoids as Anti-Inflammatory Agents for Skin Diseases.Pharmaceutics · 2025Article
- Synaptic signatures of perinatal cannabinoids: A systematic review of rodent hippocampal synaptic plasticity, learning, and memory.Drug and alcohol dependence reports · 2025Review
- Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip.Scientific reports · 2025Article
- Phytochemical Modulators of Nociception: A Review of Cannabis Terpenes in Chronic Pain Syndromes.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Variability of total THC in greenhouse cultivated dried Cannabis.Scientific reports · 2025Article
- Genotoxicity study ofToxicology reports · 2025Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from mood disorders present with treatment-resistant forms of depression, co-morbid anxiety, other psychiatric disorders and bipolar disorders. Standardized essential oils (such as that of Lavender officinalis) have been shown to exert clinical efficacy in treating anxiety disorders. As endocannabinoids are suggested to play an important role in major depression, generalized anxiety and bipolar disorders, Cannabis sativa was suggested for their treatment. The endocannabinoid system is widely distributed throughout the body including the brain, modulating many functions. It is involved in mood and related disorders, and its activity may be modified by exogenous cannabinoids. CB1 and CB2 receptors primarily serve as the binding sites for endocannabinoids as well as for phytocannabinoids, produced by cannabis inflorescences. However, 'cannabis' is not a single compound product but is known for its complicated molecular profile, producing a plethora of phytocannabinoids alongside a vast array of terpenes. Thus, the "entourage effect" is the suggested positive contribution derived from the addition of terpenes to cannabinoids. Here, we review the literature on the effects of cannabinoids and discuss the possibility of enhancing cannabinoid activity on psychiatric symptoms by the addition of terpenes and terpenoids. Possible underlying mechanisms for the anti-depressant and anxiolytic effects are reviewed. These natural products may be an important potential source for new medications for the treatment of mood and anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.